Nisa Investment Advisors LLC Sells 6,395 Shares of Intuitive Surgical, Inc. $ISRG

Nisa Investment Advisors LLC lessened its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,271 shares of the medical equipment provider’s stock after selling 6,395 shares during the period. Nisa Investment Advisors LLC’s holdings in Intuitive Surgical were worth $37,114,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Harfst & Associates Inc. raised its position in Intuitive Surgical by 5.2% during the third quarter. Harfst & Associates Inc. now owns 4,290 shares of the medical equipment provider’s stock valued at $1,744,000 after purchasing an additional 212 shares in the last quarter. Diversify Advisory Services LLC lifted its stake in Intuitive Surgical by 6.3% during the third quarter. Diversify Advisory Services LLC now owns 27,479 shares of the medical equipment provider’s stock worth $11,757,000 after purchasing an additional 1,640 shares during the last quarter. Petredis Investment Advisors LLC lifted its stake in Intuitive Surgical by 0.3% during the third quarter. Petredis Investment Advisors LLC now owns 11,634 shares of the medical equipment provider’s stock worth $4,731,000 after purchasing an additional 35 shares during the last quarter. Miller Financial Services LLC boosted its holdings in shares of Intuitive Surgical by 12.0% in the 3rd quarter. Miller Financial Services LLC now owns 2,084 shares of the medical equipment provider’s stock worth $847,000 after purchasing an additional 224 shares in the last quarter. Finally, Norway Savings Bank boosted its holdings in shares of Intuitive Surgical by 11.3% in the 3rd quarter. Norway Savings Bank now owns 3,619 shares of the medical equipment provider’s stock worth $1,472,000 after purchasing an additional 366 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 1.1%

Intuitive Surgical stock opened at $438.00 on Wednesday. The firm has a fifty day simple moving average of $392.96 and a two-hundred day simple moving average of $409.06. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88. The company has a market capitalization of $154.74 billion, a PE ratio of 50.17, a P/E/G ratio of 3.27 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. The firm had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The company’s revenue for the quarter was up 21.7% compared to the same quarter last year. During the same period last year, the firm earned $2.40 earnings per share. As a group, equities analysts expect that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Mark Brosius sold 77 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $375.57, for a total transaction of $28,918.89. Following the transaction, the executive vice president directly owned 881 shares in the company, valued at $330,877.17. This trade represents a 8.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 1,089 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total value of $407,765.16. Following the transaction, the vice president owned 1,026 shares in the company, valued at approximately $384,175.44. The trade was a 51.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 12,370 shares of company stock worth $4,891,989 in the last 90 days. 0.60% of the stock is currently owned by company insiders.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q3 revenue increased approximately 22% year over year to $3.05 billion, exceeding the roughly $2.91 billion analyst consensus. Non-GAAP earnings were $3.00 per share, well above estimates near $2.61–$2.65 and up from $2.40 a year earlier. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Underlying demand remained robust: worldwide procedures grew about 15%, da Vinci procedures rose roughly 14%, Ion procedures increased about 31%, and da Vinci placements climbed to 546 from 427 a year earlier. These trends support the company’s recurring instruments, accessories and service revenue. Intuitive Announces Third Quarter Earnings
• Positive Sentiment: Management plans to extend instrument life beginning in 2027, potentially lowering hospitals’ procedure costs and broadening robotic-surgery adoption, although this may support longer-term growth more than near-term revenue. Why ISRG Is Lowering Instrument Costs
• Neutral Sentiment: Operating leases represented 54% of second-quarter da Vinci placements, up from 49% a year earlier. Leasing may accelerate hospital adoption, but it also means Intuitive funds equipment upfront and collects returns over time. Does Leasing Make Growth More Durable or More Capital Intensive?
• Negative Sentiment: GAAP net income fell to $523 million, or $1.49 per share, from $704 million, or $1.95, after Intuitive recorded a $450 million pre-tax, or $347 million after-tax, charge tied to a proposed antitrust settlement. Court approval is still required, adding uncertainty. Antitrust Settlement Charge Overshadows Q3 Growth
• Negative Sentiment: The company narrowed its 2026 da Vinci procedure-growth outlook, prompting concerns that growth could moderate despite the quarterly beat. The legal charge and guidance update overshadowed otherwise strong results. Intuitive Surgical Stock Slides Despite Earnings Beat

Analyst Ratings Changes

ISRG has been the topic of several recent research reports. BMO Capital Markets reiterated an “outperform” rating on shares of Intuitive Surgical in a research report on Monday, July 20th. Wells Fargo & Company reissued an “overweight” rating and set a $487.00 price objective (down from $654.00) on shares of Intuitive Surgical in a report on Friday, July 17th. KeyCorp restated an “overweight” rating on shares of Intuitive Surgical in a research report on Wednesday, August 12th. Leerink Partners cut their target price on Intuitive Surgical from $573.00 to $454.00 and set an “outperform” rating for the company in a research note on Friday, July 17th. Finally, HSBC lowered Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 target price for the company. in a research note on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $498.83.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.